Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Debuts Eliquis Rival In Canada

Apo-Apixaban Version Is First Generic Alternative Available

Executive Summary

Apotex has introduced Canada’s first generic version of Eliquis in the form of its Apo-Apixaban product. The launch comes after the firm was also among a wave of Aubagio teriflunomide generics to hit the Canadian market.

You may also be interested in...



BMS Plans Appeal After Sandoz And Teva Eliminate UK Eliquis Patent

While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.

ANDA Filers Lose Again On Eliquis Patents With Monopoly Set For 2028

ANDA filers that went to trial over Bristol Myers Squibb and Pfizer’s Eliquis blockbuster face a seven-year wait to launch their generic products after the US Court of Appeals for the Federal Circuit upheld a lower court decision.

EMA Re-Examines Decisions On Prestige’s Trastuzumab And Synchron Studies

Following decisions by the EMA’s CHMP to deny Prestige Biopharma a marketing authorization for its trastuzumab biosimilar and to suspend the marketing authorizations of dozens of generics due to concerns over bioequivalence tests, the European regulator has confirmed it will review the opinions.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel